Search - tctmd.com

Displaying 1 - 20 of 46

Sort: Relevancy | Date

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

News Daily News

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

December 26, 2025

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

News Daily News

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

May 17, 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

May 10, 2024

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

October 16, 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

January 20, 2023

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

August 05, 2022

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

Class I Recall for Cordis’ Super Torque Catheters with Radiopaque Markers

News Daily News

Class I Recall for Cordis’ Super Torque Catheters with Radiopaque Markers

Michael O'Riordan

September 23, 2021

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

September 17, 2020

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

September 28, 2019

FDA Class I Recall for PTA Catheters Due to Unexpected Balloon Bursting

News Daily News

FDA Class I Recall for PTA Catheters Due to Unexpected Balloon Bursting

Yael L. Maxwell

June 18, 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

News Conference News ISET 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

January 29, 2019

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

January 25, 2019

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

January 23, 2019

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

News Conference News VIVA 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

November 09, 2018

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

News Daily News

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

October 05, 2018

News Industry News

Veryan Medical receives PMA approval for BioMimics 3D

October 05, 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

September 24, 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

September 22, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.